Omico Will Precisely Match Patients to George Clinical Oncology Trials SYDNEY, July 28, 2023 – George Clinical recognises and applauds its collaborative partner Omico, with whom it is aligned in a common goal to revolutionize oncology clinical trial access for patients and improve the efficiency of study enrollment, on the launch of their landmark program […]
Read MoreMedidata, a Dassault Systèmes company, recently announced George Clinical is implementing Medidata’s cloud-based clinical solutions – Rave Grants Manager – to improve tracking and management of budgets. Medidata’s solution will also empower George Clinical to bring operational efficiency and improve patient recruitment by sites. The implementation will give George Clinical’s global clients the usage of […]
Read MoreSYDNEY, June 27, 2023 – George Clinical and EPS Corporation (EPS), a global CRO based in Japan are collaborating on a rare Japanese academia-led global study seeking to advance treatments for unmet needs in Asian populations. In 2019 George Clinical and EPS formed a strategic partnership to help expand their operations across the Asia-Pacific region. […]
Read MoreGeorge Clinical recently received the award for Clinical Research Team of the Year at the 7th Annual Citeline Awards held in Boston, MA. As a 2023 winner, the George Clinical team won recognition for a multi-site program in the Asia Pacific region that recruited more than 3,000 patients across 14 sites in just seven weeks. […]
Read MoreFrost & Sullivan studied the contract research organization industry and, based on its findings, recognizes George Clinical with the 2023 Asia-Pacific Competitive Strategy Leadership Award. George Clinical is a global CRO with world class expertise in kidney research, oncology and neurology and remains fully committed to growing their strong presence in Asia-Pacific which is where the company has […]
Read MoreSYDNEY, May 4, 2023 – George Clinical announces that the company has initiated preparations in Australia for two oncology Phase 1b trials that will examine a Hummingbird Bioscience precision therapy program targeting HER3, a potent driver of tumor growth and resistance against cancer drugs, in biomarker-selected patient populations, including lung cancer. George Clinical is providing […]
Read MoreThe 4th Annual Chronic Kidney Disease Drug Development (CKD3) Summit saw a select group of scientists, clinical researchers and experts from industry and regulatory agencies gathered face-to-face for the first time since the pandemic. Excitement and enthusiasm were evident as these experts networked and collaborated on how the latest scientific research is being applied to […]
Read MoreThe UPcare Group is now advancing to human trials with George Clinical with trials to begin soon. UPcare’s human trials are based on their previous pre-clinical and real-world data. Pre-clinical trial results conducted by The Doherty institute in 2020 indicated that compounds used in UPCare’s formulations and products are up to 99.99% effective at inhibiting […]
Read MoreOVERLAND PARK, KS., March 1, 2022 – George Clinical announces the expansion of its renal scientific leadership into Latin America with the addition of subject matter expert Hernán Trimarchi, MD, PHD, FACP, FASN. Dr. Trimarchi’s research focuses on glomerular diseases, particularly proteinuria and podocyturia, IgA nephropathy, focal segmental glomerulosclerosis, and Fabry disease. He is Head […]
Read MoreExceptional kidney and metabolic scientific leadership network provides continuity, communication and cultural expertise in long-term global trial program. Background The National Institute of Diabetes and Digestive and Kidney Diseases (NIH) estimates that more than one in seven people with kidney disease have anemia, increasing their chance of developing heart problems and strokes. The prevalence […]
Read More
